New pill HLD-0915 takes on tough prostate cancer

NCT ID NCT06800313

Recruiting now Disease control Sponsor: Halda Therapeutics OpCo, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental oral drug called HLD-0915 in men with metastatic prostate cancer that has worsened after other treatments. The trial has two phases: Phase 1 checks safety and the best dose, while Phase 2 looks at how well it controls the cancer. About 190 men will take part across multiple groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HLD-0915 (oral drug)
What this could lead to: If successful, this could provide a new oral treatment option for men with metastatic prostate cancer that has stopped responding to other therapies.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the drug may not prove effective or safe enough for wider use. Side effects and limited benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma epithelial neoplasm male reproductive organ cancer male reproductive system disorder Male Urogenital Diseases metastatic prostate carcinoma prostate cancer Urogenital Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC PROSTATE CANCER PROSTATE CANCER (ADENOCARCINOMA) PROSTATE CANCER METASTATIC DISEASE

Contacts and locations

Locations

Carolina Urologic Research Center, LLC
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Duke University Medical Center
RECRUITING

Durham, North Carolina, 27710, United States
Florida Cancer Specialists
RECRUITING

Sarasota, Florida, 34232, United States
Massachusetts General Hospital
RECRUITING

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
NEXT Austin
RECRUITING

Austin, Texas, 78758, United States
Royal Marsden Hospital
RECRUITING

Sutton, Surrey, SM2 5PT, United Kingdom
SCRI Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
START Midwest, LLC
RECRUITING

Grand Rapids, Michigan, 49546, United States
Sarah Cannon Research Institute at HealthONE
RECRUITING

Denver, Colorado, 80218, United States
The University of Texas M.D. Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Yale - New Haven Hospital - Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.